Back to search results

Cognitive Processing Therapy for PTSD in Sexual and Gender Minority Individuals

This study is testing two types of Cognitive Processing Therapy (CPT) for Post Traumatic Stress Disorder (PTSD) in sexual or gender minority individuals. One is standard CPT, and the other is CPT-LEAP, which is adapted to address stress from lived experiences. The goal is to see if CPT-LEAP better helps with PTSD symptoms. You may be able to join if you are 18 or older, identify as a sexual or gender minority, have a current PTSD diagnosis, experience moderate stress from lived experiences, and live in Massachusetts. If you take psychiatric medication, your dose must be stable for one month before joining. The study is currently unclear on its recruitment status and plans to enroll 52 participants.

Study design
This study will involve two phases. In Phase 2, participants will be randomly assigned to receive either standard CPT or CPT-LEAP, with 26 participants in each group.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your PTSD symptoms will be measured immediately after treatment and again 3 months later.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07714083

Cognitive Processing Therapy for Posttraumatic Stress Disorder and Co-occurring Lived Experience Stress

Not Yet Recruiting
NAAges 18+InterventionalTreatment
Boston University
~52 participants
Updated 2026-07-20 on ClinicalTrials.gov
What's tested:Standard CPTCPT-LEAP

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Post traumatic stress disorder symptoms (PTSD)
Measured over immediately after treatment, 3 months

Conditions

Post Traumatic Stress Disorder

Explore related trials

Post-Traumatic Stress Disorder

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Cara Herbitter, PhD, MPH · PRINCIPAL_INVESTIGATOR · Psychiatry CABUSM and National Center for PTSD, VA Boston Healthcare System

Who to contact

Cara Herbitter, PhD, MPH
[email protected]
857-364-6528
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Current diagnosis of PTSD
Self-identification as a sexual or gender minority (SGM) individual
Endorsement of SGM stress experiences with moderate distress
For patients who take psychiatric medication, stable dose one month prior to enrollment
Reside in Massachusetts.

Exclusion

Current active suicidal or homicidal ideation with intent or plan
Unstable bipolar disorder/current mania
Unstable psychotic disorder/current psychosis
Current severe substance use that warrants immediate medical attention
Cognitive impairment or organic disorder (e.g., advanced dementia, severe traumatic brain injury) that impairs ability to complete CPT procedures
Past completion of CPT or current trauma-focused treatment
Unwillingness to consent to audio or video recording of assessment and treatment sessions

What this trial measures

  • Post traumatic stress disorder symptoms (PTSD)immediately after treatment, 3 months

    Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 (CAPS-5). The CAPS-5 includes 20 items assessing PTSD symptom severity. Total scores range from 0-80 with higher scores indicating more severe PTSD symptoms.